The litigation targets claims made by Unicycive Therapeutics during the six-month period ending June 29, 2026. The complaint alleges that the company failed to audit its third-party manufacturing vendor, leaving it without a reasonable basis to claim that FDA-cited deficiencies had been resolved. According to the filing, this lack of oversight created an undisclosed risk that the FDA would demand further information, ultimately jeopardizing the regulatory approval timeline for the drug candidate OLC.

Legal counsel for the potential class asserts that these omissions rendered the company's public statements regarding its business and operational prospects materially misleading. Shareholders interested in participating as lead plaintiffs must contact the Law Offices of Howard G. Smith before the November 2, 2026 deadline. Those who do not wish to act as lead plaintiffs are not required to take any immediate steps to remain part of the potential class.